<DOC>
	<DOCNO>NCT01008007</DOCNO>
	<brief_summary>The purpose study assess safety effect Viusid ( bag 4 gram ) administration treatment acute fever viral etiology diagnose clinical , hematologic serologic parameter . The duration open randomize phase 2 clinical trial 6 day . The estimated number person acute fever viral etiology recruit randomize study 200 . The primary outcome measure : platelet , leukocyte granulocyte count assess begin end study .</brief_summary>
	<brief_title>Viusid Adults With Acute Fever Viral Etiology</brief_title>
	<detailed_description />
	<mesh_term>Fever</mesh_term>
	<criteria>Acute fever viral etiology le 72 hour progression Signed informed consent . Patients treatment antioxidant . Inability swallow content Viusid bag</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Viusid</keyword>
	<keyword>Dietary supplement</keyword>
	<keyword>Acute fever</keyword>
	<keyword>Viral etiology</keyword>
</DOC>